DDInter625 DDInter1435
Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain. It has been determined that endometriosis is one of the most common gynecologic disorders in the United States [A35868, A35869, F801]. In particular, estimates suggest that one in ten women of reproductive age is affected by endometriosis and experience debilitating pain symptoms [A35868, A35869, F801]. Moreover, women who are affected by this
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Elagolix {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Elagolix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Osilodrostat
Elagolix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Macimorelin
Elagolix {u} may lead to a major life threatening interaction when taken with {v} Rifampicin
Elagolix {u} may lead to a major life threatening interaction when taken with {v} Tazemetostat
Elagolix may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Elagolix may lead to a major life threatening interaction when taken with Rifampicin
Elagolix may lead to a major life threatening interaction when taken with Tazemetostat